In patients with normal renal function, SGLT2 inhibitors are known to enhance potassium excretion by the kidney through a combination of mechanisms (increased sodium and water delivery to the distal nephron, enhanced glycosuria, and stimulation of aldosterone) and are also known to provide cardiorenal protection in patients with CKD. Here, SLC5A2 is linked to chronic kidney disease.